CKS2 and endometrial carcinoma: Kaplan-Meier survival analysis for 535 endometrial carcinoma patients without adjuvant treatment in RNA-seq dataset of TCGA database indicated no significant impact of CKS2 expression on the survival time of endometrial carcinoma patients (hazard ratio (HR) = 0.832, p = 0.536) (Figure 4C).